HZNP - Horizon Therapeutics' Krystexxa shows potential as durable therapy in uncontrolled gout

Horizon Therapeutics ([[HZNP]] -0.4%) presents new data from the ongoing PROTECT study, which provides further insight into utility of KRYSTEXXA (pegloticase injection) as a treatment for people with uncontrolled gout (chronic gout refractory to conventional therapies) who have undergone a kidney transplant. At time of data cut, estimated glomerular filtration rate (eGFR), a key indicator of kidney function, remained stable for all patients throughout KRYSTEXXA treatment.In the 10 patients with Week 24 eGFR measurements, the mean eGFR was 41.6 ± 10.6 mL/min/1.73 m2 (median of 41.0) at baseline and 43.8 ± 11.9 mL/min/1.73 m2 (median of 46.6) at Week 24, with a mean improvement of 2.3 ± 8.1 mL/min/1.73 m2 during the treatment.Further, through health assessment questionnaires, patients reported clinically meaningful reductions in pain (average reduction of 26.7 +/- 30.3 from baseline of 35.9 +/- 30.2 on a scale of 0-100) and disability (average reduction of 0.2 +/- 0.5 from

For further details see:

Horizon Therapeutics' Krystexxa shows potential as durable therapy in uncontrolled gout